Single-cell protein is a growing opportunity for Asian markets

February 20, 2020
Emerging Ecosystems in Agrifood and Health More...
by Laura Krishfield
Average importance

Calysseo, a joint venture (JV) between Calysta and Adisseo, will develop and produce Calysta's SCP aquafeed ingredients, branded FeedKind, exclusively for Asian markets. The JV also plans to construct a FeedKind production facility in China that will come online in 2022 and initially produce 20,000 MT of FeedKind protein per year. The facility's full-scale capacity is projected to be 100,000 MT per year. This news has two major takeaways: 1) Feed developers are displaying commitment to the growth of alternative protein industries, and 2) SCP production will quickly grow to support major aquaculture markets. Clients should look for opportunities to engage with SCP, as production will become commercially relevant in the near term.

For the original news article, click here .

Further Reading

New algae facility in Malaysia looks very similar to Algenol's vertical PBRs

News Commentary | August 22, 2019

Sarawak Biodiversity Centre (SBC) and Mitsubishi Corporation unveiled their joint algae project in Malaysia after starting R&D in 2012. The project was designed to test the suitability of algae cultivation in tropical climates, with Chitose Group providing the algae strain, which is collected ... Not part of subscription

Avril and Terrena seek business opportunity in organic meal through joint venture Oleosyn Bio

News Commentary | October 02, 2019

Oleosyn, a joint venture between Avril and Terrena, will produce organic soybean meal, organic sunflower, and organic rapeseed for poultry feed and an organic table oil. The meal will be produced primarily from crops grown in France and within a production facility previously used by Avril's feed ... Not part of subscription

Unibio gains investment from Mitsubishi Corporation for commercial expansion of single-cell protein (SCP)

News Commentary | December 05, 2019

While the announcement does not comment on the amount raised, Unibio (Lux Take: Positive) will use the funding to support the commercial expansion of its SCP production. Currently, the company has a full‑scale facility being commissioned in Russia, and it recently announced plans to construct a new ... Not part of subscription